-
公开(公告)号:US20230067037A1
公开(公告)日:2023-03-02
申请号:US17239086
申请日:2021-04-23
Applicant: Genentech, Inc.
Inventor: Peter DRAGOVICH , Thomas PILLOW , Robert Anthony BLAKE , Ingrid WERTZ
IPC: A61K47/68 , A61K31/427 , A61K31/5517 , A61K31/661
Abstract: The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
-
公开(公告)号:US20250084096A1
公开(公告)日:2025-03-13
申请号:US18913161
申请日:2024-10-11
Applicant: Genentech, Inc.
Inventor: Robert Anthony BLAKE , Peter DRAGOVICH , Lewis J. GAZZARD , Susan KAUFMAN , Tracy KLEINHEINZ , Thomas PILLOW , Steven T. STABEN , Binqing WEI
IPC: C07D495/14 , A61P35/00 , C07D495/16
Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
-
公开(公告)号:US20140294868A1
公开(公告)日:2014-10-02
申请号:US14208374
申请日:2014-03-13
Applicant: GENENTECH, INC. , SPIROGEN SÀRL
Inventor: Philip Wilson HOWARD , John A. FLYGARE , Thomas PILLOW , Binqing WEI
IPC: A61K47/48 , C07D487/04 , A61K31/5517
CPC classification number: A61K47/6869 , A61K31/5517 , A61K47/6803 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61P35/00 , C07D487/04 , C07D487/16 , C07D519/00
Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
-
公开(公告)号:US20200157240A1
公开(公告)日:2020-05-21
申请号:US16696455
申请日:2019-11-26
Applicant: GENENTECH INC. , MEDIMMUNE LIMITED
Inventor: John FLYGARE , Janet GUNZNER-TOSTE , Thomas PILLOW , Brian SAFINA , Vishal VERMA , Binqing WEI , Guiling ZHAO , Leanna STABEN , Philip Wilson HOWARD , Luke MASTERSON
IPC: C07K16/30 , C07K16/28 , A61K31/5517 , A61K47/68
Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
-
公开(公告)号:US20180125997A1
公开(公告)日:2018-05-10
申请号:US15786055
申请日:2017-10-17
Applicant: MedImmune Limited , Genentech, Inc.
Inventor: Philip Wilson HOWARD , John A. FLYGARE , Thomas PILLOW , Binqing WEI
IPC: C07D519/00 , C07D487/16 , A61K31/5517
Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 43; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
-
公开(公告)号:US20200085965A1
公开(公告)日:2020-03-19
申请号:US16689286
申请日:2019-11-20
Applicant: GENENTECH, INC.
Inventor: Peter DRAGOVICH , Zhonghua PEI , Thomas PILLOW , Jack SADOWSKY , Vishal VERMA , Donglu ZHANG
IPC: A61K47/68 , A61K31/5517 , A61P35/00
Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
-
公开(公告)号:US20200017601A1
公开(公告)日:2020-01-16
申请号:US16353207
申请日:2019-03-14
Applicant: Genentech, Inc.
Inventor: Sunil BHAKTA , Hans ERICKSON , Jagath R. JUNUTULA , Katherine KOZAK , Rachana OHRI , Thomas PILLOW
IPC: C07K16/32 , A61K47/68 , C07K16/18 , C07K16/28 , C07K16/30 , A61K51/10 , C07K16/00 , C07K16/40 , G01N33/58
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
-
公开(公告)号:US20160130358A1
公开(公告)日:2016-05-12
申请号:US14851348
申请日:2015-09-11
Applicant: Genentech, Inc.
Inventor: Sunil BHAKTA , Hans ERICKSON , Jagath R. JUNUTULA , Katherine KOZAK , Rachana OHRI , Thomas PILLOW
IPC: C07K16/32 , C07K16/28 , C07K16/30 , G01N33/58 , A61K49/00 , A61K51/10 , A61K47/48 , C07K16/00 , C07K16/40
CPC classification number: C07K16/32 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6849 , A61K47/6869 , A61K51/10 , A61K2039/505 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/3069 , C07K16/3092 , C07K16/40 , C07K2317/40 , C07K2317/73 , C07K2317/94 , G01N33/582
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
Abstract translation: 在重链或轻链中包含游离半胱氨酸氨基酸的半胱氨酸改造的抗体是通过诱变亲本抗体的核酸序列并用半胱氨酸代替一个或多个氨基酸残基来编码半胱氨酸改造的抗体来制备的; 表达半胱氨酸改造的抗体; 并分离半胱氨酸改造的抗体。
-
公开(公告)号:US20210221821A1
公开(公告)日:2021-07-22
申请号:US17198240
申请日:2021-03-10
Applicant: Genentech, Inc.
Inventor: Robert Anthony BLAKE , Peter DRAGOVICH , Lewis J. GAZZARD , Susan KAUFMAN , Tracy KLEINHEINZ , Thomas PILLOW , Steven T. STABEN , Binqing WEI
IPC: C07D495/14 , C07D495/16 , A61P35/00
Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
-
公开(公告)号:US20190175749A1
公开(公告)日:2019-06-13
申请号:US16271549
申请日:2019-02-08
Applicant: GENENTECH, INC.
Inventor: Peter DRAGOVICH , Zhonghua PEI , Thomas PILLOW , Jack SADOWSKY , Vishal VERMA , Donglu ZHANG
IPC: A61K47/68 , A61P35/00 , A61K31/5517
Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
-
-
-
-
-
-
-
-
-